CGTX - Cognition Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CGTX is currently covered by 2 analysts with an average price target of $9.05. This is a potential upside of $8.71 (2561.76%) from yesterday's end of day stock price of $0.34.

Cognition Therapeutics's activity chart (see below) currently has 2 price targets and 6 ratings on display. The stock rating distribution of CGTX is 100% BUY.

Stock Analyst Price Targets - Review

Highest price target for CGTX is $2, Lowest price target is $1, average price target is $7.5.

Most recent stock forecast was given by JAY OLSON from OPPENHEIMER on 27-Mar-2024. First documented stock forecast 03-Nov-2021.

Best performing analysts who are covering CGTX - Cognition Therapeutics:

Jay Olson Mayank Mamtani Aydin Huseynov

Currently out of the existing stock ratings of CGTX, 4 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$9

$6.63 (279.75%)

$9

1 years 3 months 6 days ago
(27-Mar-2024)

0/3 (0%)

$7.18 (394.51%)

Buy

$6

$3.63 (153.16%)

$10

1 years 10 months 19 days ago
(14-Aug-2023)

0/2 (0%)

$4.47 (292.16%)

Buy

$27

3 years 5 months 9 days ago
(24-Jan-2022)

0/1 (0%)

$14.47 (115.48%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CGTX (Cognition Therapeutics) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on CGTX (Cognition Therapeutics) with a proven track record?

JAY OLSON

Which analyst has the current lower performing score on CGTX (Cognition Therapeutics) with a proven track record?

AYDIN HUSEYNOV

Which analyst has the most public recommendations on CGTX (Cognition Therapeutics)?

Jay Olson works at OPPENHEIMER and has 6 price targets and 5 ratings on CGTX

Which analyst is the currently most bullish on CGTX (Cognition Therapeutics)?

Jay Olson with highest potential upside - $6.63

Which analyst is the currently most reserved on CGTX (Cognition Therapeutics)?

Mayank Mamtani with lowest potential downside - -$0

Cognition Therapeutics in the News

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc.  (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related...

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine’s potential across degenerative disease indications PURCHASE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc.  (NASDAQ: CGTX), a clinical-stage company developing...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?